Unlock instant, AI-driven research and patent intelligence for your innovation.

Medicine composition for treating coronary heart disease and its prepn process, use and guality control method

A technology for coronary heart disease and drugs, applied in the field of pharmaceutical compositions for the treatment of coronary heart disease and its preparation, use and quality control, can solve the problems of drug side effects, unsatisfactory, unacceptable by patients, and long-term use

Inactive Publication Date: 2006-11-08
JIANGSU KANION PHARMA CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, clinical practice has proved that simple western medicine treatment is often unsatisfactory, especially the side effects of the medicine, which make it difficult for patients to accept and take it for a long time.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine composition for treating coronary heart disease and its prepn process, use and guality control method

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0072] Embodiment 1: Preparation method Take 1100 grams of Rhodiola rosea medicinal material, add 8 times the amount of water and boil for 1.5 hours, filter, add 6 times the amount of the dregs of the medicine, boil for 1.5 hours, filter, combine the two medicinal liquids, concentrate into an extract, The amount of the paste obtained is about 190-200g, and the relative density is 1.2-1.25 (measured at 60°C). Take 1 part of the extract and 1.25-1.35 parts of starch, mix well, dry below 80°C, pulverize, make granules with ethanol at an appropriate concentration, and dry. The whole grain is packed into capsules, and 1000 capsules are obtained, each weighing 0.38g, which is equivalent to 1.1g of crude drug.

Embodiment 2

[0073] Example 2: The embodiment of identification method takes 1 g of the capsule content obtained above, puts it in a flask, adds 30 ml of ethanol with a concentration of 95%, heats to reflux for 1 hour, filters, concentrates the filtrate to dryness, and adds 2 ml of ethanol to the residue to dissolve , as the test solution. In addition, take the salidroside reference substance and add ethanol to make a solution containing 1mg per 1ml, as the reference substance solution, according to the thin-layer chromatography ("The People's Republic of China Pharmacopoeia 1990 Edition Part One") test, absorb the above two 2 to 4 μl of each of these solutions were spotted on the same thin layer of silica gel G containing sodium carboxymethylcellulose as a binder, and ethyl acetate-methanol-formic acid (9:1:0.8) was used as a developer. Unfold, take out to dry, spray with 1% FeCl 3 -1% Potassium ferricyanide (1: 1) solution, check under sunlight, in the chromatogram of the test product, ...

Embodiment 3

[0074] Embodiment 3: the embodiment of content determination method Accurately weigh about 2g of the capsule content prepared above, put in a flask, add 30ml of ethanol, heat and reflux for 1 hour, filter, filter residue is washed three times with 20ml of ethanol, combine the filtrate and concentrate to as far as possible. Dry, add 5ml of water to the residue to dissolve, add to a polyamide column (80-120 mesh, 5g dry packing, φ1.5cm), elute with water, accurately collect 25ml of the eluate, and use it as the test solution. The reference substance solution and the test solution 5--10μl are injected into the liquid chromatograph, and the peak area is measured under the conditions described in the system suitability test, and the external standard method is used to calculate it.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a medicine for treating coronary heart disease and its preparation method, use and quality control method. The active ingredient of the medicine is salidroside, which can be made from rhodiola rosea. The developer of salidroside identified by thin-layer chromatography is ethyl acetate-methanol-formic acid (9:1:0.8), and the color developer is 1% FeCl 3 -1% potassium ferricyanide (1: 1); the measuring conditions of salidroside content wherein is determined by high performance liquid chromatography is: be filler with octadecylsilane bonded silica gel, methyl alcohol-water-glacial acetic acid ( 7:93:1) is the mobile phase, the flow rate is 0.9ml / min, the detection wavelength is 276nm, the column temperature is 40°C, and the number of theoretical plates should not be less than 7000 based on the salidroside peak.

Description

technical field [0001] The invention relates to a pharmaceutical composition for treating coronary heart disease and its preparation method, application and quality control method. Background technique [0002] Coronary heart disease is a common cardiovascular disease. As early as the 1960s, its incidence rate was constantly rising in some western countries, and it became the top of human death. For example, in the United States, which has a population of only 200 million, about 700,000 people die from coronary heart disease every year, accounting for 1 / 3 of the death toll, known as the "first killer". In my country, with the continuous improvement of people's living standards, the aging of the population and the relative lag of preventive health care work, the prevalence, morbidity and mortality of coronary heart disease have continued to rise. According to the national census data in 1973, the average incidence rate of coronary heart disease was only 6.46%. By 1975, the ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7028A61K36/41A61P9/10G01N33/15G01N30/02
Inventor 萧伟杨寅戴翔翎凌娅瘳正根
Owner JIANGSU KANION PHARMA CO LTD